Vitiligo – Pipeline Review, 2024

Vitiligo is a type of skin disease in which melanocytes, the pigment cells of the skin are destroyed, resulting in loss of skin colour or depigmentation in different areas of the body. The rate and extent of colour loss from vitiligo varies from patient to patient and can affect people of any age group. The disease can also affect the hair, eyes, and inside of the mouth. The disease can be triggered by events such as stress, sunburn or exposure to certain chemicals, or any disorder of the immune system that attacks the melanocytes.

Current treatment of vitiligo includes use of sunscreen, phototherapy, corticosteroids and drugs that affects the immune system. Calcipotriene, a form of vitamin D for topical application, can be used along with corticosteroids and light treatment. Also, ointment which contain tacrolimus or pimecrolimus, drugs can be effective on smaller patches of depigmented skin as they are calcineurin inhibitors.

Many pharmaceutical giants and academic research institutes are focusing on the development of novel treatment for vitiligo. For instance; PF-06651600, which is being studied by Pfizer Inc. is currently in phase 2 clinical trials to evaluate the safety and efficacy of PF-06651600 in the treatment of active non-segmental vitiligo. 

At present, around 44% of the pipeline candidates for vitiligo are in the phase 2 stage. More than half of the studies are sponsored by academic and research institutes. 

To know how our report can help streamline your business, Speak to Analyst

Report Description

The report on ‘Vitiligo – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Vitiligo. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Vitiligo.

The report on ‘Vitiligo – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Vitiligo
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Vitiligo
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary